Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488813 | 0.90 | RAB9A (0.55) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9127353 | 0.87 | MAPK14 (0.55) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9123661 | 0.87 | LTA4H (0.55) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3019351 | 0.86 | LTA4H (0.54) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9124265 | 0.85 | LTA4H (0.60) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL488397 | 0.84 | LTA4H (0.53) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6079764 | 0.83 | LTA4H (0.54) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6079375 | 0.82 | LTA4H (0.61) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9747086 | 0.80 | LTA4H (0.58) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL488951 | 0.80 | NPC1 (0.61) | LTA4HMAPK14RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| WO-2018184976-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND USE OF SAME | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | WO | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-5409943-A | [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1995-04-25 | — | — | US | disclosed |
| EP-0625143-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015055-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | LTA4H 3821/4885MAPK14 1828/4885RAB9A 3796/4885 |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | AADAC, TNNI3, TNNT2 | LTA4H 3622/4885MAPK14 1626/4885RAB9A 3684/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | LTA4H 4259/4885MAPK14 210/4885RAB9A 2731/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | LTA4H 3789/4885MAPK14 152/4885RAB9A 2752/4885 |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | LTA4H 3821/4885MAPK14 1828/4885RAB9A 3796/4885 |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | TNNI3, CYP11B2, PPIP5K2 | LTA4H 3169/4885MAPK14 1438/4885RAB9A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.